Piramal Pharma Solutions Unveils Ambitious $90M Expansion Project in the U.S.

Piramal Pharma Solutions $90M Expansion Plan

Piramal Pharma Solutions is gearing up for a significant transformation as it embarks on a $90 million investment to expand two of its facilities in the United States. This ambitious expansion reinforces the company's commitment to leading the pharmaceutical industry through innovation and demand-driven solutions.

The expansion focuses on the Riverview, Michigan, and Lexington, Kentucky facilities, both of which play a crucial role in Piramal Pharma's comprehensive antibody-drug conjugate (ADC) offering, aptly named ADCelerate™. By enhancing commercial-scale manufacturing capabilities, Piramal aims to elevate both the efficiency and capacity of these vital locations.

Groundbreaking Ceremony

On June 25, 2025, the company celebrated the groundbreaking for the expansion of its sterile injectables development and manufacturing facility. The ceremony was attended by key figures, including local officials and company executives. This marked a pivotal moment not only for Piramal but also for the surrounding communities, highlighting the potential for economic growth and job creation in the region.

Facility Highlights

The Riverview facility specializes in the development and manufacturing of high potency active pharmaceutical ingredients (HPAPIs) and services associated with drug substance development. The expansion will focus on creating a commercial-scale suite dedicated to manufacturing payload-linkers, which are essential for securing the efficacy and stability of ADC therapies. Expected to be operational by late 2025, this new suite will position Piramal at the forefront of biologics manufacturing.

On the other hand, the Lexington facility focuses on the fill/finish operations for sterile injectables. It will not only add 24,000 square feet of new manufacturing space but also enhance its capabilities with new laboratory facilities and advanced machinery, including a state-of-the-art filling line and commercial-size lyophilizers. Upon completion of the expansion, projected for late 2027, the Lexington facility will elevate its manufacturing capacity from 104 to over 240 product batches annually.

Responding to Market Trends

This expansion is timely, as the sterile injectables market is rapidly evolving, driven by increased medical needs and advancements in scientific research. The shift towards sterile injectable solutions enhances patient safety and efficacy. Similarly, the rising popularity of ADC therapies necessitates a bolstering of manufacturing and development capabilities to meet new patient care challenges. This strategic $90 million investment will enable Piramal to capitalize on these trends effectively.

Nandini Piramal, Chairperson of Piramal Pharma, emphasized the importance of this expansion, stating, “Our research indicates that the sterile injectables market will surpass $20 billion by 2028. This presents a crucial opportunity for us to enhance our services and establish ourselves as a trusted partner in biologic manufacturing.”

Peter DeYoung, CEO of Piramal Global Pharma, reiterated the importance of adapting to the market's growing demands for ADCs, which have become critical in precision immunotherapy strategies against certain cancers.

Community Impact and Future Growth

Notably, the expansion will lead to the creation of approximately 40 new full-time jobs, contributing positively to the local economy and reinforcing Piramal's commitment to harnessing local resources for sustained innovation. Mayor Linda Gorton of Lexington expressed her enthusiasm, confirming that Piramal's expansion illustrates the city’s potential as a thriving hub for the pharmaceutical industry.

Commerce Lexington's President and CEO, Bob Quick, echoed similar sentiments, highlighting the region's strong positioning in the biotech and life sciences sector due to these growth initiatives.

In conclusion, Piramal Pharma Solutions’ $90 million investment in this expansion signifies a bold step toward enhancing its capabilities. By aligning its manufacturing operations with market demands, Piramal not only ensures its competitive advantage but also ushers in a new era of patient-centric solutions that promise to alleviate health burdens worldwide.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) operates as a Contract Development and Manufacturing Organization (CDMO), providing end-to-end solutions across the drug life cycle, emphasizing innovation, quality, and responsiveness to client needs. With a network of facilities spanning North America, Europe, and Asia, PPS is committed to excellence in all aspects of pharmaceutical development and manufacturing, including biologics and complex drug formulations.